News

The tgAAC09 vaccine candidate utilizes an adeno-associated virus (AAV) vector to deliver genes encoding HIV proteins and is designed to stimulate an immune response against HIV. Modest immune

Enzon is also entitled to receive an additional one-time milestone payment of $15 million in 2012 should certain royalty recognition levels be met for Peg-Intron. A portion of

The agreement grants Schering-Plough exclusive worldwide rights for the development and commercialization of PeriCor’s lead compound, acadesine. Financial terms of the transaction were not disclosed. Acadesine is currently

The company claims that Biferonex is a pH neutral and human serum albumin (HSA) free formulation providing an interferon beta treatment solution for patients suffering from relapsing remitting

In its approvable letter to Solvay Pharmaceuticals, the FDA stated that the company would need to provide additional clinical data and chemistry, manufacturing and controls information prior to

The company says that, unlike oral bisphosphonate therapies that have to be taken daily, weekly or monthly, Reclast is given as a once-yearly 15-minute intravenous (IV) infusion. This

The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high-risk prostate cancer. The study began in late 2006 and will enroll

Soliris is approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can

Orphan drug designation entitles Atlanta-based Tikvah to seven years of market exclusivity for phenylbutyrate for the treatment of patients with spinal muscular atrophy (SMA). Additional incentives for orphan